{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:00Z","timestamp":1791252780703,"version":"4.1.0"},"reference-count":31,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>&lt;p&gt;Introduction: Treatment for relapsed\/refractory AL amyloidosis (AL) is an unmet need. The safety and efficacy of belantamab mafodotin (BLM) in multiple myeloma are known, whereas in AL data are limited. Methods: We report a multi-center cohort of AL patients receiving BLM, and review all previous data on BLM therapy in AL. Results: Twelve patients with a median of 3 (range 2\u20139) prior lines of therapy were included. The overall hematological response rate (ORR) was 75% (9\/12), including 5 complete responses. Six of the 10 evaluable patients had organ responses. The median event-free survivals\/overall survivals were 22.3 and 28.8 months, respectively. Grade 3 toxicities were mostly infections and keratopathy, occurring in 7\/12 (58%). Hematological toxicities were rare. No grade 4\/5 toxicities occurred. The review of the previous series reveals BLM provides an ORR of 60\u201383% with similar rates of corneal toxicity. Conclusion: BLM, being an off-the-shelf therapy, with acceptable toxicity even in frail patients, may be a valuable option in AL, with a high ORR, and a signal for durable responses and high-quality organ responses. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000541594","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T12:00:53Z","timestamp":1727870453000},"page":"419-426","source":"Crossref","is-referenced-by-count":8,"title":["Belantamab Mafodotin in Relapsed\/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature"],"prefix":"10.1159","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-7278","authenticated-orcid":false,"given":"Eyal","family":"Lebel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vainstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamir","family":"Shragai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Magen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Assayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-4482","authenticated-orcid":false,"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008737"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26569"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.213900"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12973"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01317-y"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2023.2169124"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1767566"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19042"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04890-z"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00717-2"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19286"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185861"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1868810"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20381"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.100"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127332"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0637"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2021.2002841"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061710"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003783"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022937"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/aha\/article-pdf\/doi\/10.1159\/000541594\/4294050\/000541594.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000541594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:02:50Z","timestamp":1758297770000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000541594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2025,7,31]]}},"URL":"https:\/\/doi.org\/10.1159\/000541594","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}